Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129961 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL4822309 | 1.00 | USP2 (0.42) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL27567585 | 0.87 | USP2 (0.45) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL14959559 | 0.86 | HPGD (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL14452943 | 0.86 | HPGD (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL1184732 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL2392691 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL796400 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL193100 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT | |
| SCHEMBL30289051 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2NR1H2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50527-E1 | Covalent inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2005026156-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| EP-1441729-A1 | PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR | SMITHKLINE BEECHAM PLC (GB) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003041711-A1 | PIPERAZINE BIS-AMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE OREXIN RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
| CN-1232457-A | 1,4-heterocyclic metalloprotease inhibitors | PROCTER & GAMBLE (US) | 1999-10-20 | — | — | CN | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| CN-1085216-A | Have the diphenyl-oxazole, thiazole and the imdazole derivatives that suppress the adenosine resorption | BRISTOL MYERS SQUIBB CO (US) | 1994-04-13 | — | — | CN | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | USP2 1637/4885SMN1; SMN2 3583/4885NR1H2 3475/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | USP2 254/4885SMN1; SMN2 3761/4885NR1H2 3774/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | USP2 254/4885SMN1; SMN2 3761/4885NR1H2 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.